Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an update.
Ondine Biomedical Inc. announced that its CEO, Carolyn Cross, and her husband, through The Pennycook Family Trust, have increased their stake in the company by purchasing 200,775 shares. This transaction signifies a vote of confidence in the company’s ongoing operations, including its Phase 3 clinical trial for regulatory approval in the US, potentially strengthening its market position and reassuring stakeholders about its future prospects.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company is focused on developing a range of investigational products using its proprietary technology, with applications including nasal photodisinfection, chronic sinusitis, ventilator-associated pneumonia, and burns. Ondine’s nasal photodisinfection system, Steriwave®, is approved in Canada and several other countries and is undergoing clinical trials in the US with Fast Track status from the FDA.
YTD Price Performance: 37.14%
Average Trading Volume: 525,352
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £48.48M
See more insights into OBI stock on TipRanks’ Stock Analysis page.
